XML 50 R35.htm IDEA: XBRL DOCUMENT
v3.22.2

Revenue Interest Financing Liability - Additional Information (Details) - USD ($) $ in Thousands |  | 3 Months Ended | 6 Months Ended
--- | --- | --- | ---
May 03, 2022 | Jun. 30, 2022 | Jun. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |
Investors right to receive royalties termination description |  |  | The investors’ right to receive royalties on net sales will terminate when the investors have aggregate payments equal to 200% of the Investment Amount. In addition, at any time after the earlier of (i) April 30, 2024 and (ii) the date that the payment for erosive esophagitis regulatory approval is made, the Company has the right to make a cap payment equal to 200% of the Investment Amount less any royalties already paid, at which time the agreement will terminate.
Investors receipt description |  |  | If the investors have not received aggregate payments of at least 100% of the Investment Amount by December 31, 2028, and at least 200% of the Investment Amount by December 31, 2037, each a Minimum Amount, then the Company will be obligated to make a cash payment to the investors in an amount sufficient to gross the investors up to the applicable Minimum Amount.
Default obligation description |  |  | Upon the occurrence of an event of default taking place prior to April 1, 2025, between April 1, 2025, and April 1, 2028, and after April 1, 2028, the Company is obligated to pay 1.30 times Investment Amount, 1.65 times Investment Amount, and 2.0 times investment amount, respectively, less any amounts the Company previously paid pursuant to the agreement.
Change in control description |  |  | Upon the occurrence of a change in control event taking place prior to the earlier of April 1, 2024, or FDA approval of vonoprazan for erosive esophagitis, the Company is obligated to pay 200% of the Investment Amount plus either 15% of the Investment Amount if occurrence prior to May 3, 2023, or plus 30% of the Investment Amount if occurrence thereafter.
Gross proceeds |  | $ 100,000 |
Transaction costs |  | 4,554 |
Net proceeds |  | 95,400 | $ 95,446
Revenue interest financing liability |  | $ 98,103 | $ 98,103
Revenue Interest Financing Agreement |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |
Percentage of aggregate payments on investment amount to investors on net sales | 200.00% |  |
Percentage of investor share of royalty in net sales | 10.00% |  |
Revenue Interest Financing Agreement | Initial Investors NQ, Sagard, and Hercules |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |
Funds received from initial closing | $ 100,000 |  |
Revenue Interest Financing Agreement | Initial Investors NQ, Sagard, and Hercules | Maximum |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |
Investors funding amount | 260,000 |  |
Revenue Interest Financing Agreement Funding upon FDA Approval at any Time Prior to December 31, 2022 | Initial Investors NQ, Sagard, and Hercules | Maximum |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |
Investors funding commitment potential amount available upon EE approval | 15,000 |  |
Revenue Interest Financing Agreement Funding upon Achievement of Sales Milestone at any Time Prior to June 30, 2024 | Initial Investors NQ, Sagard, and Hercules | Maximum |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |
Investors funding commitment potential amount available upon achievement of sales milestone | 25,000 |  |
Revenue Interest Financing Agreement, Funding Commitment On or Before March 31, 2024 | Initial Investors NQ, Sagard, and Hercules |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |
Investors additional funding amount upon FDA approval of vonoprazan for treatment of erosive esophagitis | $ 160,000 |  |
Revenue Interest Financing Agreement Percentage On Investment Amount by December 31, 2037 | Minimum |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |
Percentage of aggregate payment on investment amount to investors | 200.00% |  |
Revenue Interest Financing Agreement Percentage on Investment Amount On December December 31, 2028 | Minimum |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |
Percentage of aggregate payment on investment amount to investors | 100.00% |  |
Revenue Interest Financing Agreement Upon Occurrence of Event of Default Prior to April 1, 2025 |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |
Percentage of aggregate payment on investment amount to investors | 130.00% |  |
Revenue Interest Financing Agreement Upon Occurrence of Event of Default between April 1, 2025, and April 1, 2028 |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |
Percentage of aggregate payment on investment amount to investors | 165.00% |  |
Revenue Interest Financing Agreement Upon Occurrence of Event of Default after April 1, 2028 |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |
Percentage of aggregate payments on investment amount to investors on net sales | 200.00% |  |
Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April 1, 2024 or FDA Approval |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |
Percentage of aggregate payments on investment amount to investors on net sales | 200.00% |  |
Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April 1, 2024 or FDA Approval If Occurrence Prior May 3, 2023 |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |
Additional percentage to be paid with obligated payment on investment amount | 15.00% |  |
Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April 1, 2024 or FDA approval If occurrence is Thereafter to May 3, 2023 |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |
Additional percentage to be paid with obligated payment on investment amount | 30.00% |  |

X
- Definition Additional percentage to be paid with obligated payment on investment amount. + References No definition available. + Details
Name: | phat_AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount
Namespace Prefix: | phat_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Change in control description. + References No definition available. + Details
Name: | phat_ChangeInControlDescription
Namespace Prefix: | phat_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Default obligation description. + References No definition available. + Details
Name: | phat_DefaultObligationDescription
Namespace Prefix: | phat_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Funds received from initial closing. + References No definition available. + Details
Name: | phat_FundsReceivedFromInitialClosing
Namespace Prefix: | phat_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Gross proceeds from revenue interest financing agreement. + References No definition available. + Details
Name: | phat_GrossProceedsFromRevenueInterestFinancingAgreement
Namespace Prefix: | phat_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Investor additional funding amount upon approval. + References No definition available. + Details
Name: | phat_InvestorAdditionalFundingAmountUponApproval
Namespace Prefix: | phat_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Investors funding amount. + References No definition available. + Details
Name: | phat_InvestorsFundingAmount
Namespace Prefix: | phat_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Investors funding commitment potential amount available upon achievement of sales milestone. + References No definition available. + Details
Name: | phat_InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone
Namespace Prefix: | phat_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Investors funding commitment potential amount available upon approval. + References No definition available. + Details
Name: | phat_InvestorsFundingCommitmentPotentialAmountAvailableUponApproval
Namespace Prefix: | phat_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Investors receipt description. + References No definition available. + Details
Name: | phat_InvestorsReceiptDescription
Namespace Prefix: | phat_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Investors right to receive royalties termination description. + References No definition available. + Details
Name: | phat_InvestorsRightToReceiveRoyaltiesTerminationDescription
Namespace Prefix: | phat_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Net proceeds from revenue interest financing transaction. + References No definition available. + Details
Name: | phat_NetProceedsFromRevenueInterestFinancingTransaction
Namespace Prefix: | phat_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Payment of transaction costs. + References No definition available. + Details
Name: | phat_PaymentOfTransactionCosts
Namespace Prefix: | phat_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of aggregate payments on investment amount to investors on net sales. + References No definition available. + Details
Name: | phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales
Namespace Prefix: | phat_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of aggregate payments on investment amount to investors. + References No definition available. + Details
Name: | phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors
Namespace Prefix: | phat_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of investor share of royalty in net sales. + References No definition available. + Details
Name: | phat_PercentageOfInvestorShareOfRoyaltyInNetSales
Namespace Prefix: | phat_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue interest financing liability. + References No definition available. + Details
Name: | phat_RevenueInterestFinancingLiability
Namespace Prefix: | phat_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=phat_InitialInvestorsNqSagardAndHerculesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |